Vestibular schwannoma (VS) is an intracranial tumor that causes significant morbidity, including
Vestibular schwannoma (VS) is a non-malignant tumor originating from Schwann cells of the vestibular nerve. VSs occur either sporadically and unilaterally, or bilaterally as hallmark tumors of neurofibromatosis type 2 (NF2). VSs result in significant morbidity, including hearing loss, tinnitus and dizziness. As these tumors grow, they can cause facial paralysis and other cranial neuropathies, as well as death from brainstem compression. Although microsurgery and stereotactic radiation remain the mainstay of treatment for growing VSs, observation is an acceptable option for newly diagnosed and non-growing tumors. At present, since the majority of VSs are diagnosed early, observation is the most common initial choice 1 . Such a choice is justified because both microsurgery and stereotactic radiation therapy carry significant risks, including the risk of irreversible ipsilateral hearing loss. Despite the slow progression of the disease, no pharmacologic treatments have been approved for VS, highlighting the need to develop effective and well-tolerated pharmaceutical therapies.
Several clinical trials for NF2-associated VSs are currently underway, targeting key pathways important for disease pathogenesis 2, 3 . However, these trials have relied on expensive chemotherapeutic agents with substantial adverse effects, including cardiovascular toxicity 4 , so widespread use of these drugs to treat non-malignant tumors is unlikely. The unmet medical need to identify safe agents with minimal adverse effects to treat VS has motivated our study of dietary agents with potential anti-tumoral activities. Dietary agents found in fruit and vegetables have been shown to interfere with multiple cellular signaling pathways important in cancer pathogenesis, Scientific RepoRts | 6:36215 | DOI: 10.1038/srep36215
and several of these agents are capable of not only preventing but even treating some cancers 5 . We focus on sulforaphane, a dietary agent extracted from cruciferous vegetables, and its potential to inhibit VS growth. Sulforaphane (SFN) is an isothiocyanate found in cruciferous vegetables, such as broccoli. SFN has been shown to exhibit chemoprotective effects for various tumors, including those of the prostate, lung, breast and colon, in vitro and in vivo [6] [7] [8] . These studies have shown that SFN significantly affects cell survival and leads to apoptosis through a variety of molecular mechanisms, including the potent inhibition of histone deacetylase (HDAC) [9] [10] [11] . As there have been no reports examining the effect of SFN on vestibular schwannoma, here we characterize the ilnhibitory effects of SFN on VS cells in vitro using primary human VS cells and VS-derived cell lines, and in vivo using a mouse model with a murine schwannoma allograft.
Results
Sulforaphane inhibits the proliferation of primary human vestibular schwannoma cells and an NF2-derived cell line in vitro. After 48 hours of incubation with SFN (10 μ M), BrdU was used to assess proliferation in cells grown from three different primary human VSs, compared to untreated controls (Fig. 1A) . SFN substantially and significantly (p < 0.001) reduced BrdU incorporation by primary VS cells, consistent with an anti-proliferative effect. This inhibitory effect of SFN was confirmed using two different cell lines and a different assay. Specifically, human HEI-193 cells (Fig. 1B) and mouse SC4 cells (Fig. 1C) were treated with 5, 10, 15 or 25 μ M of SFN or vehicle control (DMSO) for 48 hours, and cell viability was assessed using an MTT assay. SFN inhibited cell viability in a dose-dependent manner.
Sulforaphane induces apoptosis in human vestibular schwannoma cells. Human HEI-193 cells were used to quantify the effect of SFN on apoptosis using annexin V-propidium iodide (PI) staining and TUNEL staining. In annexin V-PI staining assays, the relative strength of fluorescein isothiocyanate (FITC) and PI (FL4) fluorescence reflects cell health and is depicted in 4 quadrants ( Fig. 2A(a) ), HEI-193 cells treated with 10 μ M SFN ( Fig. 2A(b) and 20 μ M SFN ( Fig. 2A(c) ) had significantly higher proportions of apoptotic cells (Al2 + Al4), as summarized in Fig. 2A(d) .
Sulforaphane-induced apoptosis in HEI-193 cells was demonstrated further using TUNEL staining in situ, which detects DNA fragmentation. A significant increase in both DNA fragmentation and perinuclear apoptotic body formation were seen in HEI-193 cells treated with 10 μ M SFN compared to control cells treated with vehicle only (Fig. 2B) .
Apoptotic assays based on staining characteristics ( Fig. 2A ) and DNA fragmentation (Fig. 2B ) were complemented by measuring proteins involved in apoptosis by Western blot (Fig. 2C) . Specifically, we measured expression of caspase-9, caspase-3, and caspase-3-mediated poly (ADP-ribose) polymerase (PARP), as well as the cleaved forms of these proteins. In HEI-193 cells treated with 20 μ M SFN for 48 h relative to controls, the expression of pre-caspase-9 (precursor form) significantly decreased, while the expression of cleaved caspase-9 increased. Cleavage of caspase-3 was used as a marker of cells undergoing apoptosis, while the observed cleavage of PARP was consistent with caspase-mediated apoptosis. Taken together, these data confirm SFN-induced apoptosis in HEI-193 cells via induction of caspase activity.
Sulforaphane induces cell cycle arrest. Because arresting the cell cycle can have a therapeutic effect for various neoplasms 10, 12 , we studied whether sulforaphane arrested the cell cycle of HEI-193 cells (Fig. 3 ). SFN significantly arrested schwannoma cells in the G2/M phase of the cell cycle in a concentration-dependent manner (Fig. 3A) . When comparing 0 versus 20 μ M SFN, the proportion of HEI-193 cells in G2/M phase increased from 15.57 ± 0.79 to 47.68 ± 2.96% (p < 0.01), implying G2/M arrest (Fig. 3B ).
Sulforaphane inhibits histone deacetylase activity and increases ERK in schwannoma cells.
Because sulforphane is a potent inhibitor of histone deacetylase (HDAC) in several malignancies 7 , we studied whether it had a similar effect on non-malignant schwannoma cells. HDAC activity was inhibited by SFN in a dose-dependent manner in HEI-193 cells (Fig. 4A) . Moreover, expression of acetyl histone H3 was significantly increased in a dose-dependent manner, as assessed by Western blot (Fig. 4B) . Regulation of the AKT/mTOR signaling kinases and extracellular signal-regulated kinase (ERK) has previously been observed in response to SFN treatment in breast cancer, prostate cancer, and hepatoma 6, 13, 14 . SFN induced activation of ERK in HEI-193 cells but had no effect on AKT/mTOR (Fig. 4C) .
Sulforaphane inhibits schwannoma growth in vivo.
To examine the effect of SFN on schwannomas in vivo, mouse SC4 Nf2 −/− Schwann cells were allografted to nude mice. Mice were treated with SFN or vehicle control via intraperitoneal administration five times per week for 6 weeks, after which we compared tumor volumes between groups. No statistically significant change in mean body weight between SFN-treated (n = 8 mice) and control animals (vehicle only, n = 8 mice) was observed over the course of the study, suggesting that SFN was not toxic (Fig. 5A) . SFN-treated mice (25 mg/kg) showed a statistically significant inhibition of tumor growth at all time points from 16 days after treatment on. At the completion of treatment a 27.2% reduction in tumor volume (p < 0.05) was observed compared with the vehicle control group (Fig. 5B) . Tumor weight was also significantly lower at the completion of treatment, with the SFN group exhibiting a 25.8% reduction in mean tumor weight relative to the vehicle control group (p < 0.05; Fig. 5C ).
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Discussion
We have shown, for the first time, that a dietary extract, sulforaphane, is therapeutic against human vestibular schwannoma cells in vitro and mouse schwannoma cells in vivo. Significant insights into the pathways underlying VS pathogenesis have led to a variety of new therapeutic targets for intervention in schwannoma. Targeted molecular therapies for VS using EGFR/ErBb2 (lapatinib), mTOR (everolimus), and VEGF inhibitor (bevacizumab) have been examined in patients with NF2 [15] [16] [17] . However, the cost and toxicity associated with these treatments activity in NF2-deficient schwannoma and meningioma cells, though neither has been tested in primary VS cells or in in vivo models 21 . Recent studies have identified a variety of micronutrients present in fruits and vegetables, including curcumin, resveratrol, genistein, diallyl sulfide, S-allyl cysteine, allicin, lycopene, capsaicin, diosgenin, 6-gingerol, ellagic acid, ursolic acid, silymarin, anethol, catechins, eugenol, limonene, beta carotene, and SFN, which appear to limit tumor growth, suggesting a mechanism by which dietary constituents may exert anti-carcinogenic activity 5, 22 . Here, we sought to identify compounds with inhibitory effects on schwannoma cells at doses consistent with their natural concentrations. We found that SFN had inhibitory effects on primary human vestibular schwannoma cells and a human NF2-derived VS cell line in vitro, as well as on an in vivo allograft model of VS.
HDAC inhibitors are emerging as a new class of antitumor drugs, due to their ability to promote differentiation, induce cell cycle arrest, and trigger apoptosis 23, 24 . HDAC inhibitors have been shown to inhibit multiple intracranial tumors both in vitro and in vivo through a variety of mechanisms 25, 26 . Among these, a novel HDAC inhibitor, AR42, has shown inhibitory activity against NF2-associated tumors via the induction of apoptosis 27, 28 . SFN has also been shown to inhibit HDAC activity in several human cancers, as evidenced by acetylation of histones H3 and H4, two common markers for successful HDAC inhibition 9, 10 . Our data presented here show that SFN treatment results in successful upregulation of acetylated histone H3 in VS cells, increased apoptosis, and cell cycle arrest, consistent with HDAC inhibition.
Given the complexity of the signaling pathways downstream of merlin/NF2, a number of potential therapeutic targets have been proposed 3 . The MAPK/ERK and AKT-mTOR pathways are two of the major downstream signaling pathways in schwannomas 29 . Several studies have shown that HDAC inhibitors may suppress these pathways in some tumors 30, 31 ; specifically, AR42, a novel HDAC inhibitor, has been shown to reduce VS proliferation through AKT signaling 27 . Additionally, it has been reported that SFN inhibits cell proliferation via activation of ERK in prostate tumors and hepatomas 6, 7 . Our data support the conclusion that SFN induces activation of ERK, without affecting AKT-mTOR in VS cells. Although dietary agents can be used in their natural forms to inhibit tumor progression, large doses are often necessary to achieve significant therapeutic outcomes. While these agents are pharmacologically safe in most situations, one of the main concerns is the lack of bioavailability. However, the bioavailability of these compounds should not be evaluated in the same manner as synthetic compounds, as many of these agents exhibit biological responses at serum concentrations that are otherwise undetectable in vitro 5 . It is known that dietary intake of sulforaphane translates to micromolar concentrations (0.1~10 μ M) of the compound in various cells 8 , and doses required for HDAC inhibition and apoptosis induction appear to be much higher. However, SFN has been shown to accumulate in cells and reach to millimolar concentrations 8 . More trials will be needed to validate the usefulness of SFN either alone or in combination for the treatment of VS.
Taken together, the data presented here demonstrate the inhibitory effects of SFN on VS cells in vitro and in vivo. To the best of our knowledge, this is the first report showing that SFN exerts antitumor activity against Culture of primary human vestibular schwannoma cell and NF2-derived cell line. Using sterile technique, freshly harvested human VS tissue was rinsed in phosphate buffered saline (PBS) and dissected in culture medium consisting of Dulbecco's Modified Eagle's medium with Ham's F12 mixture (DMEM/F12), 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1% GlutaMAX. VS tissue was then dissociated in hyaluronidase and collagenase (all Life Technologies, Carlsbad, CA, USA) overnight, and cultured for 2-4 weeks, as described previously 32 . Informed consent was obtained from all patients. The study protocols were approved by the Human Studies Committee of Massachusetts General Hospital and Massachusetts Eye and Ear Infirmary, and conducted in accordance with the Helsinki Declaration. In addition to a primary human VS cell culture, two cell lines were used: 1) HEI-193 cells, an immortalized cell line derived from the vestibular schwannoma of a human NF2 patient, and 2) Nf2 −/− SC4 cells, a mouse Schwann cell line (both gifts from the House Ear Institute, Los Angeles, CA, USA). The cell lines were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.
Cell proliferation assay: BrdU incorporation.
To study proliferation of primary human VS cell lines, cells were incubated with 0 (control) or 10 μ M SFN for 48 h, and then treated with 50 mg/mL bromodeoxyuridine (BrdU) (Invitrogen, Carlsbad, CA, USA) for 20 h. The cells were fixed, and the nuclear membranes were permeabilized with 1% Triton-X for 10 min, followed by 2N hydrochloric acid for 20 min. Primary antibodies against BrdU (AbD) (Serotec, Puchheim, Germany) and anti-rat IgG (Life Technologies) were used. Hoechst 33342 dye (hereafter abbreviated Hoechst, Invitrogen) were used to stain nuclei. BrdU-and Hoechst-stained nuclei were counted in 3-5 fields, and the ratio of BrdU-positive to Hoechst-positive nuclei was used to determine the proliferation rate in vitro.
Cell viability assay. and SC4 cells were seeded in 96-well plates at 5 × 10 3 and 3 × 10 3 cells/well, respectively. After 24 h, the medium was replaced with serum-free medium and cells were incubated with various concentration of DL-SFN for 48 h. To quantify cell viability and metabolic activity, a calorimetric MTT [3-(4,5-dimethhylthiaoly)-2,5-diphenyltetrazolium bromide] (5 mg/mL) assay was used. Forty μ g/mL of MTT solution (Sigma-Aldrich) in PBS was added to each well for 4 h at 37 °C. The culture medium containing MTT was then discarded. Visible formazan crystals were dissolved in 100 μ L of DMSO, followed by shaking for 30 min at room temperature in the dark. The optical density (OD) was measured at 595 nm using a microplate reader. All experiments were repeated at least 3 times.
Scientific RepoRts | 6:36215 | DOI: 10.1038/srep36215 p-ERK, ERK (all from Cell Signaling Technology), and tubulin (EMD Millipore) overnight at 4 °C. Membranes were then washed in TBS-T, and incubated in horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse antibodies, as appropriate, for 2 h at room temperature. Protein bands were detected by an ECL Plus Kit (Bio-Rad).
In vivo tumorigenesis. Six-week-old female BALB/c nude mice (Nara Biotech Co., Seoul, Korea) were maintained under specific pathogen-free conditions and fed verified mouse chow. To cultivate tumors, SC4 Nf2 −/− Schwann cells were detached by trypsinization, collected in DMEM medium containing 10% FBS, and resuspended at a density of 3.4 × 10 5 cells/mL in serum-free medium. A total volume of 0.3 mL (containing 1 × 10 5 SC4 cells) was injected into the axillary region between the shoulder and chest wall. SFN (25 mg/kg) or an equal volume of DMSO (control group) was administered intraperitoneally 5 times per week for 6weeks. Each group consisted of eight mice. The tumor growth was evaluated using a caliper and tumor volume was estimated using the following formula: length (mm) × width (mm) × height (mm)/2. On the day after the final treatment, the animals were sacrificed, the solid tumors excised, and the weight of the tumors was measured. All animal work was performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of Korea Research Institute of Bioscience and Biotechnology.
Statistical analysis. All data are presented as the mean ± standard error of mean (SEM). The independent t-test or one-way analysis of variance (ANOVA) with posthoc comparison using Bonferroni's correction was employed for statistical analyses. The significance level was set at corrected p < 0.05. SPSS (version 14.0; SPSS, Inc, Chicago, Ill, USA) and R (version 3.1.3, The R Foundation for Statistical Computing, Vienna, Austria) were used to complete all analyses.
